ACET earnings analysis
What we found in ACET's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Adicet Bio, Inc. reported a decline in operational performance for the fiscal year ended December 31, 2025, showcasing substantial losses, with a diluted EPS of -$1.91 in Q4 2025, down from -$5.44 in Q2 2025. The company continues to face challenges in revenue generation; however, it is optimistic about advancements in its clinical pipeline, which could provide avenues for future growth.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Decline in Losses
- The diluted EPS improved sequentially to -$1.91 in Q4 2025 from -$5.44 in Q2 2025, indicating potential operational efficiencies.
- Cost Reductions
- Total operating expenses decreased significantly, contributing to the improved loss figures.
- Strong Market Position
- As of June 30, 2025, the company's market value stood at approximately $50.5 million, reflecting ongoing investor interest despite losses.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Ongoing Financial Losses
- The company reported substantial losses throughout 2025, with diluted EPS ranging from -5.01 to -1.91 over the quarters.
- Revenue Generation Challenges
- Adicet reported zero revenue in Q4 2025 and continues to face significant hurdles in establishing a reliable revenue stream.
- Regulatory Risks
- Ongoing regulatory risks related to clinical trials, which could impede the drug approval process.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-1.91
What they said about what is next.
Management has not provided specific numeric guidance for future periods, maintaining an outlook of ongoing operational financing needs.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Adicet Bio, Inc. reported a net loss improvement of 28% YoY in Q1 2026, with a diluted EPS of -$1.88 compared to -$4.96 in Q1 2025. Total operating expenses decreased by 28% to $21.57 million as R&D and G&A expenses…
- 10-K · March 12, 2026
- Adicet positions itself as a leader in allogeneic gamma delta CAR‑T therapies with a prioritized autoimmune program (prula‑cel) and a next‑generation oncology candidate (ADI‑212). The 10‑K highlights positive early…
- 10-Q · May 6, 2025
- Adicet reported a Q1 2025 net loss per share of $(0.31), beating the consensus estimate of $(0.34) by $0.03. The company ended the quarter with $28,133 in cash and cash equivalents and $122,306 in short-term treasury…
- 10-Q · August 13, 2024
- Adicet Bio reported a Q2 net loss of $29.9M (EPS -$0.33) versus a loss of $32.4M (EPS -$0.75) in Q2 2023, showing a sequential improvement in per-share loss driven by lower R&D expense and a larger share base. Cash and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACET makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever